Italy fines drug company for excessive pricing
Italy’s Competition Authority has fined Leadiant Biosciences €3.5 million for abusing its dominance by overcharging the national health service for an orphan drug, less than a year after the Dutch antitrust enforcer penalised the drugmaker for the same conduct.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.